Cargando…

A Scoring System Based on Laboratory Parameters and Clinical Features to Predict Unfavorable Treatment Outcomes in Multidrug- and Rifampicin-Resistant Tuberculosis Patients

BACKGROUND: The growth of antibiotic resistance to Mycobacterium TB represents a major barrier to the goal of “Ending the global TB epidemics”. This study aimed to develop and validate a simple clinical scoring system to predict the unfavorable treatment outcomes (UTO) in multidrug- and rifampicin-r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Jisong, Luo, Hong, Nie, Qi, Hu, Shengling, Yu, Qi, Wang, Xianguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840374/ https://www.ncbi.nlm.nih.gov/pubmed/36647452 http://dx.doi.org/10.2147/IDR.S397304

Ejemplares similares

The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study
por: Yu, Qi, et al.
Publicado: (2023)

Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management
por: Prasad, Rajendra, et al.
Publicado: (2018)

Predictive model of unfavorable outcomes for multidrug-resistant tuberculosis
por: Arroyo, Luiz Henrique, et al.
Publicado: (2019)

In Vitro Activity of Rifampicin and Verapamil Combination in Multidrug-Resistant Mycobacterium tuberculosis
por: Demitto, Fernanda de Oliveira, et al.
Publicado: (2015)

Transmission and Drug Resistance Genotype of Multidrug-Resistant or Rifampicin-Resistant Mycobacterium tuberculosis in Chongqing, China
por: Zhao, Bing, et al.
Publicado: (2022)

Development and validation of a scoring system for the prediction of HIV drug resistance in Hubei province, China
por: Yan, Jisong, et al.
Publicado: (2023)

Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
por: Zhang, Zehua, et al.
Publicado: (2014)

Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
por: Cai, Xingshan, et al.
Publicado: (2022)

Treatment of Infection as a Core Strategy to Prevent Rifampicin-Resistant/Multidrug-Resistant Tuberculosis
por: Reuter, Anja, et al.
Publicado: (2023)

Correction: In Vitro Activity of Rifampicin and Verapamil Combination in Multidrug-Resistant Mycobacterium tuberculosis
por: Demitto, Fernanda de Oliveira, et al.
Publicado: (2015)

Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana
por: Tembo, Blackson Pitolo, et al.
Publicado: (2019)

Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013–2015: A retrospective cohort study
por: Chaves-Torres, Ninfa Marlen, et al.
Publicado: (2021)

Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
por: Salaam-Dreyer, Zubeida, et al.
Publicado: (2021)

Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis
por: Choi, Hongjo, et al.
Publicado: (2023)

Factors Associated with Non-Adherence for Prescribed Treatment in 201 Patients with Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in Anhui Province, China
por: Zhu, Qing-Qing, et al.
Publicado: (2022)

Validation of an indigenous assay for rapid molecular detection of rifampicin resistance in presumptive multidrug-resistant pulmonary tuberculosis patients
por: Gomathi, N.S., et al.
Publicado: (2020)

Pyrazinamide resistance in rifampicin discordant tuberculosis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2022)

Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa
por: Loveday, Marian, et al.
Publicado: (2020)

Secondary erythrocytosis following drugs used in rifampicin/multidrug-resistant tuberculosis: a retrospective cohort study
por: Tesfamariam, Sirak, et al.
Publicado: (2021)

Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia
por: Woldeyohannes, Demelash, et al.
Publicado: (2019)

High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
por: Ragonnet, Romain, et al.
Publicado: (2017)

Efflux Activity Differentially Modulates the Levels of Isoniazid and Rifampicin Resistance among Multidrug Resistant and Monoresistant Mycobacterium tuberculosis Strains
por: Machado, Diana, et al.
Publicado: (2018)

Rifampicin-Resistant Multidrug-Resistant Tuberculosis Cases in Selected Hospitals in Western Oromia, Ethiopia: Cross-Sectional Retrospective Study
por: Zewdie, Olifan, et al.
Publicado: (2020)

Health-Related Quality of Life in Tuberculosis Patients in Eritrea: Comparison Among Drug-Susceptible and Rifampicin/Multidrug-Resistant Tuberculosis Patients
por: Araia, Zenawi Zeramariam, et al.
Publicado: (2021)

Rifampicin Resistance in Tuberculosis Outbreak, London, England
por: Jenkins, Claire, et al.
Publicado: (2005)

Chylothorax in a child with rifampicin-resistant tuberculosis
por: McLaren, B, et al.
Publicado: (2019)

Navigating a Path to Rifampicin Resistance in Tuberculosis
por: Agarwal, Sakshi, et al.
Publicado: (2023)

Scale-up of Multidrug-Resistant Tuberculosis Laboratory Services, Peru
por: Shin, Sonya S., et al.
Publicado: (2008)

Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden
por: Gopalan, Narendran, et al.
Publicado: (2021)

Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014–2018
por: Bahizi, Gloria, et al.
Publicado: (2021)

Primary and acquired multidrug-resistant tuberculosis: Predictive factors for unfavorable treatment outcomes in Rio de Janeiro, 2000–2016
por: Bhering, Marcela, et al.
Publicado: (2020)

Prevalence of rifampicin resistance by automated Genexpert rifampicin assay in patients with pulmonary tuberculosis in Yenagoa, Nigeria
por: Ikuabe, Peter Ogie, et al.
Publicado: (2018)

Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2019)

Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis
por: Wu, Chunli, et al.
Publicado: (2023)

Accurate Detection of Rifampicin-Resistant Mycobacterium Tuberculosis Strains
por: Song, Keum-Soo, et al.
Publicado: (2016)

Dysphonia – the single symptom of rifampicin resistant laryngeal tuberculosis
por: Paulauskienė, Iveta, et al.
Publicado: (2016)

Comparison of GeneXpert and line probe assay for detection of Mycobacterium tuberculosis and rifampicin-mono resistance at the National Tuberculosis Reference Laboratory, Kenya
por: Aricha, S. A., et al.
Publicado: (2019)

A scoring system developed from a nomogram to differentiate active pulmonary tuberculosis from inactive pulmonary tuberculosis
por: Yu, Qi, et al.
Publicado: (2022)

Dihydroartemisinin-Loaded Chitosan Nanoparticles Inhibit the Rifampicin-Resistant Mycobacterium tuberculosis by Disrupting the Cell Wall
por: Gu, Xiujuan, et al.
Publicado: (2021)

Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii
por: Nordqvist, H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h47rnohpblt4rvp1quss6g9fuj